AIDS News and Research

RSS

Abbott Laboratories attempt to silence AIDS advocates

In a brazen attempt to silence AIDS advocates' ongoing criticism of Abbott Laboratories over its recent 400% price hike on the key AIDS drug Norvir, two prominent gay publications are buckling under pressure from Abbott to refuse to run, or significantly alter, a parody advertisement created by AIDS Healthcare Foundation (AHF) that spoofs the drug giant's media spin on their unprecedented price hike on Norvir.

16 Apr 2004

AIDS advocates and patients protest Abbott Laboratories' Norvir price hikes

A broad coalition of AIDS advocates and patients will come together in protest over Abbott Laboratories' recent unprecedented 400% price hike on Norvir (ritonavir), their key AIDS drug.

16 Apr 2004

$360,000 boost for HIV/AIDS patients in Pima County

The University of Arizona has been awarded $360,000 from the federal Ryan White CARE Act to expand its patient care services for HIV/AIDS patients in Pima County. Ryan White Early Intervention Services Clinics now are held at the University of Arizona Health Sciences Center and at Kino Hospital.

16 Apr 2004

New centre for AIDS research opens in Southampton UK

International experts on HIV/AIDS were in Southampton today (Thursday 15 April) to mark the official opening of a new Centre for AIDS Research at the city's University.

16 Apr 2004

HIV Vaccine Program to Lead Local Efforts

May 18 has been designated HIV Vaccine Awareness Day, a day to educate Americans about the need for a vaccine to prevent HIV. This year's theme is "Real People. Real Progress." Thousands of study volunteers, scientists, and health care professionals are committed to finding a safe and effective vaccine.

15 Apr 2004

Extra funding aids brain research

A healthy arrival of funds over the past couple of years has produced "endorphins" in McMaster’s "brain" that has psychology researchers very excited.

14 Apr 2004

Canadian health groups urge ban on exportation of pharmaceutical drugs from Canada to the U.S.

Canadian health groups today called on the Government of Canada to ban the exportation of pharmaceutical drugs from Canada to the U.S. The groups, who represent the interests of millions of Canadian patients, were in Washington to highlight their concerns with Internet pharmacies.

14 Apr 2004

Health Canada funds HIV/AIDS project

In Canada, it is estimated that every day one Aboriginal person becomes infected with HIV/AIDS. Partners in this project include le Centre de Santé Vallée-de-l'Or, la Régie Régionale de la santé et des services sociaux de l'Abitibi-Témiscamingue, le Service de Santé Kitcisasik, le Service de Santé Lac Simon, La clinique régionale VIH/sida and staff from MRC de la Vallée-de-l'Or.

14 Apr 2004

21st century is shaping up to be the "century of vaccines"

The 21st century is shaping up to be the "century of vaccines," as vaccine developers make striking progress against both emerging and longstanding diseases, according to Vaccines: Preventing Diseases and Protecting Health, from the Pan American Health Organization (PAHO).

14 Apr 2004

China steps up fight against AIDS

China will increase medical aid and offer free education to hundreds of children orphaned by AIDS in a central province ravaged by the deadly disease.

11 Apr 2004

Bush Administration Undermining World Health Organisation Guidelines

Since the release of President George W. Bush's Emergency Plan for AIDS Relief, the U.S. global AIDS coordinator and former CEO of Eli Lilly, Randall Tobias, and other Bush administration officials have made public remarks that question the quality of generic antiretroviral drugs and undermine international quality standards set by the World Health Organization.

11 Apr 2004

Roche announces new dosing strategy

Roche has announced results from a study demonstrating that the new boosted dosing regimen for its protease inhibitor Invirase(R) (saquinavir 1000 mg with ritonavir 100 mg twice-daily) has no significant interactions when it is co-administered with tenofovir disoproxil fumarate (300 mg once-daily).

9 Apr 2004

African summit on treatment of AIDS, tuberculosis and malaria

In Gaborone, Botswana, government officials and representatives of drug regulatory agencies from 23 nations, the research-based and generic pharmaceutical industries, public health leaders, health care providers, advocacy groups (including persons living with HIV/AIDS), academia and members of non-governmental organizations held discussions from March 29-31 on the scientific and technical principles for fixed-dose combination drug products (FDCs) for use in the treatment of AIDS, tuberculosis and malaria, the most serious infectious disease threats facing the world today.

8 Apr 2004

Doctors Likelier to Delay Prescribing Antiretroviral Drugs for Women and Minority HIV Patients

A new UCLA study finds that doctors who follow guidelines recommending the delay of antiretroviral therapy for non-adherent HIV patients are likelier to put off that treatment for Latinos, women and poor patients than they do for others. In addition, doctors are slower to prescribe protease inhibitors for African American patients whether or not the physician follows the guidelines.

4 Apr 2004

Compounds that may stop replication of T-cell leukemia virus

Researchers are analyzing several compounds that may inhibit the enzyme that is essential for the reproduction of the Human T-cell Leukemia Virus Type 1 (HTLV-I), which has infected 15 to 20 million people worldwide. The virus causes the fatal adult T-cell leukemia in up to 10 percent of those infected.

1 Apr 2004

First Canadian therapeutic HIV vaccine trial

Clinicians from the McGill University Health Centre and the Centre hospitalier de l'Université de Montréal (CHUM) are participating in the first Canadian therapeutic HIV vaccine trial. Funded by a number of public and private institutions, including the Canadian Network for Vaccines and Immunotherapeutics (CANVAC) and the Canadian Institutes of Health Research, this project will begin in April.

30 Mar 2004

Almost half of all medicines globally are used irrationally according to WHO

Almost half of all medicines globally are used irrationally. This, say medicines experts at the World Health Organization (WHO), can have severe consequences: adverse drug reactions, drug resistance, protracted illness and even death. In addition, the financial cost incurred by individuals and governments due to irrational use is unnecessary and often extremely high, particularly in developing countries where patients often pay for medicines out of pocket.

29 Mar 2004

IPM takes over Microbicide development to protect against sexual transmission of HIV

International Partnership for Microbicides (IPM) today announced that it has reached a farsighted agreement with Tibotec Pharmaceuticals Ltd, a subsidiary of Johnson & Johnson. The aim is to develop the promising compound TMC120 as a safe and effective microbicide to help protect women from infection with HIV. This agreement marks the first collaboration in the microbicide field between a major healthcare company and a public-private partnership such as IPM.

29 Mar 2004

Cryptosporidium parvum parasite could help to develope new therapies for the disease

Cryptosporidium parvum, an insidious, one-celled, waterborne parasite that lodges in the intestines of infected people and animals and for which there is currently no effective treatment, is missing key structures normally found in similar parasites, say researchers supported by the National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes of Health. The results of their genome sequencing project, could help scientists home in on new drug targets that may lead to therapies for the disease.

26 Mar 2004

Joint Research Collaboration to Predict 3-D Protein Structures and Support Drug Discovery

IBM today announced that the University at Buffalo (UB) Center of Excellence in Bioinformatics, The State University of New York, will use IBM technologies and research expertise to study the structure and behavior of human proteins. The outcome of this research could lead to more targeted drugs to treat diseases such as cancer, Alzheimer's, AIDS and multiple sclerosis.

25 Mar 2004